β-促红细胞生成素对癌症患者贫血及健康相关生活质量的影响：一项使用通用15D工具的前瞻性观察研究

Impact of Epoetin-beta on anemia and health-related quality of life in cancer patients: a prospective observational study using the generic 15D instrument.

作者信息

Mäenpää Johannna, Puistola Ulla, Riska Henrik, Sintonen Harri, Saarni Outi, Juvonen Eeva, Kellokumpu-Lehtinen Pirkko-Liisa

机构信息

Professor of Radiotherapy and Oncology, Tampere University, School of Medicine, Tampere University Hospital, PO Box 607, FI-33101 Tampere, Finland.

出版信息

Anticancer Res. 2014 May;34(5):2325-9.

PMID:24778039

Abstract

AIM

Cancer-related anemia has a negative impact on the health-related quality of life (HRQoL). Our aim was to evaluate prospectively the effect of treatment of anemia with an erythropoietin on the hemoglobin level and HRQoL in cancer patients with anemia.

PATIENTS AND METHODS

Consecutive patients (N=114) treated for the first time with epoetin (epoetin beta 30000 IU/wk, NeoRecormon®) for anemia during cancer treatment were eligible for study inclusion. Baseline characteristics were collected from patients' records. HRQoL was measured by the generic 15D instrument and fatigue by visual analogue scale (VAS) at baseline and four months from the start of the treatment with epoetin. The majority (87%) of patients had solid tumors; 69% with a metastatic disease and 89% disease with comorbidities.

RESULTS

The mean hemoglobin concentration (SD) in blood increased from 96.6 (8.9) g/L to 112.9 (21.2) g/L, by 16.5 (20.6) g/L (p<0.0001). The mean 15D score rose from 0.72 to 0.77. The change was statistically significant (p=0.0047) and clinically important. The mean fatigue VAS score decreased by 16.0 points, or from 55.4 to 38.4 (+24.4) (p<0.0001).

CONCLUSION

Correction of anemia increased the health-related quality of life in anemic cancer patients, as measured with the generic 15D instrument and the fatigue VAS.

摘要

目的

癌症相关性贫血对健康相关生活质量（HRQoL）有负面影响。我们的目的是前瞻性评估用促红细胞生成素治疗贫血对癌症贫血患者血红蛋白水平和HRQoL的影响。

患者与方法

在癌症治疗期间首次接受促红细胞生成素（促红细胞生成素β30000IU/周，利血宝®）治疗贫血的连续患者（N=114）符合研究纳入标准。从患者记录中收集基线特征。在基线以及开始使用促红细胞生成素治疗四个月时，用通用的15D工具测量HRQoL，用视觉模拟量表（VAS）测量疲劳程度。大多数（87%）患者患有实体瘤；69%患有转移性疾病，89%的疾病伴有合并症。

结果

血液中平均血红蛋白浓度（标准差）从96.6（8.9）g/L增至112.9（21.2）g/L，增加了16.5（20.6）g/L（p<0.0001）。平均15D评分从0.72升至0.77。该变化具有统计学意义（p=0.0047）且具有临床重要性。平均疲劳VAS评分降低了16.0分，即从55.4降至38.4（+24.4）（p<0.0001）。